Diagnostics

DiagnosticsLIVERFASt Clinical ManagementProduct InformationProduct DescriptionLIVERFAStTM is a noninvasive panel of tests, combining patient’s age, gender and body mass index with 10 blood biomarkers; correlated with liver conditions to generate three scores for estimating fibrosis, activity and steatosis. For each condition, LIVERFAStTM evaluates a quantitative score (0.00 to 1.00) and its estimated grade or stage, similar to the liver biopsy classification. LIVERFAStTM algorithm uses AI neural networks to optimize the clinical diagnosis according to the latest NAFLD histopathologic SAF scoring system, that covers the entire spectrum of lesions (from S0-A0-F0 to S3-A4-F4) and provides an activity score not biased by steatosis. Product BrochureDOWNLOADProduct InformationDOWNLOADInterested in this product?Request a call-backTALK TO US

DiagnosticsLIVERFASt DR DiabetesProduct InformationProduct DescriptionType 2 Diabetes is more than 2-fold higher in individuals with NAFLD and often evolves with normal liver enzymes. LIVERFAStTM accurately identifies severe fibrosis and cirrhosis in both patients with or without type 2 diabetes irrespective of liver enzyme levels. NASH related cirrhosis is disproportionately high in those with type 2 diabetes and is now on a trajectory to become the most common indication for liver transplantation in the U.S. LIVERFAStTM accurately identifies cirrhosis in subjects with all biochemistry inside the normal laboratory range. Product BrochureDOWNLOADProduct InformationDOWNLOADInterested in this product?Request a call-backTALK TO US